VEGFA and thrombotic microangiopathy: However, when anti‐VEGF drugs are used in clinical tumor therapy, blocking VEGF signaling may lead to many common adverse vascular reactions, including hypertension and renal vascular injuries, such as proteinuria and thrombotic microangiopathy.30, 40, 41